Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

55.98 -0.73 (-1.30%)

Streaming Delayed Price Updated: 12:27 PM EDT, Sep 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,270,376
Open	56.38
Bid (Size)	55.95 (100)
Ask (Size)	56.00 (400)
Prev. Close	56.71
Today's Range	55.70 - 56.96
52wk Range	50.01 - 86.74
Shares Outstanding	141,797,854
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Stay updated with the stocks that are on the move in today's after-hours session. ↗

September 04, 2026

Via Chartmill

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

September 04, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	-29.7%	-29.7%
1 Month	-1.7%	-1.7%
3 Month	-24.9%	-24.9%
6 Month	-26.0%	-26.0%
1 Year	-8.2%	-8.2%

More News

Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment ↗

September 04, 2026

Via MarketBeat

Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates ↗

July 29, 2026

Via Chartmill

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

September 03, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

September 03, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

Via The Motley Fool

Breakfast News: A Conversation With Ionis CEO ↗

August 22, 2026

Via The Motley Fool

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

August 20, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Via The Motley Fool

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗

August 14, 2026

Via The Motley Fool

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

August 08, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Ionis (IONS) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

August 04, 2026

From Pomerantz LLP

Via GlobeNewswire

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors? ↗

August 03, 2026

Via The Motley Fool

Ionis Pharmaceuticals Q2 Earnings Call Highlights ↗

July 29, 2026

Via MarketBeat

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

July 29, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis reports second quarter 2026 financial results and highlights progress on key programs

July 29, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

July 28, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

July 21, 2026

From Pomerantz LLP

Via GlobeNewswire

Cathie Wood Just Bet Big on This Biotech Stock ↗

July 18, 2026

Via The Motley Fool

Ionis to hold second quarter 2026 financial results webcast

July 15, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

July 14, 2026

From Pomerantz LLP

Via GlobeNewswire

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

July 14, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗

July 13, 2026

Via MarketBeat

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?

Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market

What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?

The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 55.98

When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 09/09/26 12:27 PM ET

What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 7.94B

How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?

Ionis Pharmaceuticals, Inc. - Common Stock has 8B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.